August 21, 2017
The former BioChemics Inc. CEO who was accused of lying to investors about the state of the company has agreed to pay the U.S. Securities and Exchange Commission $120,000 and remain off the leadership of public companies as part of a deal cleared on Friday in Massachusetts federal court.
March 25, 2015
A Massachusetts-based life sciences company was ordered Wednesday to pay $17.9 million to the U.S. Securities and Exchange Commission in a lawsuit accusing the company of selling investors millions of dollars' worth of stock by falsely suggesting that its products would soon secure the necessary regulatory approvals.
December 14, 2012
The U.S. Securities and Exchange Commission hit BioChemics Inc. with a lawsuit Friday in Massachusetts federal court, accusing the biopharmaceutical company of selling investors $9 million worth of stock by falsely suggesting that its products would soon secure the necessary regulatory approvals.